Detail akcie GENinCode Rg online

Business Summary: GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Genincode PLC revenues increased 46% to L1.4M. Net loss decreased 31% to L2.4M. Revenues reflect United Kingdom segment increase from L131K to L304K, Spain segment increase of 11% to L912K. Lower net loss reflects Medical Equipment segment loss decrease of 31% to L2.5M. Basic Earnings per Share excluding Extraordinary Items increased from -L0.04 to -L0.01.